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1. Introduction 
Ischemic heart disease (IHD) and stroke have been the world’s leading causes of death for over 15 years 
[1]. Prominent ‘traditional’ risk factors for cardiovascular disease (CVD) such as hypertension, smoking, 
diabetes and obesity have been the focus of extensive epidemiological research and subsequent public 
health action [2]. Additional research has focused on a more diverse range of acute triggers including; 
emotional stress, physical exertion, air pollution and acute infections [3]. Here we consider the effect of 
acute respiratory infections (ARIs).  
Population-level studies in a range of geographical settings show that patterns of CVD mortality and acute 
cardiovascular events mirror the seasonality of some ARIs, and persists after controlling for long-term 
incidence trends, seasonality and environmental conditions [4,5]. While the findings from these 
population-level studies suggest a link between ARIs and cardiovascular complications, stronger evidence 
comes from individual-level observational studies.  
2. Observational research studies of the association between ARIs and acute cardiovascular events 
Observational research using large electronic health record databases affords large sample sizes, and their 
longitudinal nature allows for a self-controlled case series (SCCS) study design. In SCCS studies, cases act 
as their own controls, accounting for fixed confounders, during periods of non-exposure – this is 
particularly useful when investigating associations between transient exposures and acute events. Results 
from SCCS studies have generally estimated a two to six-fold increase in risk of cardiovascular 
complications – particularly myocardial infarction (MI) and stroke – following an ARI [6-8]. Meta-
analysis, limited to case-control studies, identified ARIs were more likely to have occurred among MI 
patients, with a pooled odds ratio (OR) of 2.01, 95% confidence interval (CI) 1.47-2.76 [9].  
SCSS studies have split follow-up time, from ARI symptom onset or diagnosis to cardiovascular event, by 
days which thereby identified the length of risk. The results suggest risk lasts for up to one month 
following infection, with the highest risk in the first week after infection [6-8]. 
Risk is dependent on several factors. The severity of infection will impact the likelihood of cardiovascular 
complications; an international multicenter cohort study in patients with community acquired pneumonia 
(CAP) identified composite acute cardiovascular events were more likely following severe infection (OR 
1.74, 95% CI 1.15-2.63), with a particularly high OR seen for MI (OR 4.33, 95% CI 1.55-12.1) [10]. Case-
control and SCCS studies have largely used broad clinical definitions of ARI. Studies which use a 
microbiological definition identified an increased risk of cardiovascular complications after influenza virus 
and Streptococcus pneumoniae infection [7,8]. Host health will additionally modify risk; the majority of 
studies have been conducted among older adults with pre-existing diagnosed CVD [6,8,9]. ARIs can 
trigger acute cardiovascular events in people without known CVD [6], although it is likely that at least 
some of these events occur in people with undiagnosed atherosclerosis. 
3. Potential mechanisms  
Systemic inflammatory processes triggered by ARIs include release of pro-inflammatory cytokines which 
are key mediators of atherosclerosis and may directly impact plaque rupture through local inflammation 
[11]. Furthermore, infections induce pro-coagulant and hemodynamic effects which predispose to ischemia 
and thrombosis [11,12]. While animal models of severe pneumonia show that S. pneumoniae can invade 
the myocardium leading to cardiac injury and scarring [13], there have been few echocardiographic studies 
during severe pneumonia in humans. Autopsy studies suggest that myocardial injury, which is relatively 
rare in uncomplicated infections [14], may occur more often in fatal influenza [15].  
4. The role of influenza and pneumococcal vaccinations in reducing cardiovascular risk 
Both randomized controlled trials (RCTs) and observational studies demonstrate some CVD benefits of 
influenza vaccine. A meta-analysis of five small RCTs identified influenza vaccine reduced the risk of 
cardiovascular events within one year of follow-up (relative risk (RR) 0.64, 95% CI 0.49-0.84) [16]. A 
subgroup meta-analysis of three RCTs in patients with IHD found risk reduction predominantly in people 
with recent acute coronary syndrome compared to stable IHD [16]. Recent observational research studies 
have demonstrated similar findings; in a SCCS study among heart failure patients, influenza vaccination 
was associated with a lower risk of hospitalization due to CVD (incidence rate ratio 0.73, 95% CI 0.71-
0.76) [17]. 
The effects of pneumococcal vaccination on cardiovascular outcomes are less clear. Meta-analysis 
investigating the effect of pneumococcal vaccination on cardiovascular outcomes identified no RCTs, 
while results from observational studies were mixed [18]. In people aged ≥65 years, vaccination was 
associated with a lower risk of MI (RR 0.90, 95% CI 0.82-1.00), but no reduction in risk was identified 
among patients of all ages with high cardiovascular risk [18].  
In most high-income countries universal influenza and pneumococcal vaccination is recommended for 
adults aged ≥60-65 years. Adults under these ages are recommended to receive vaccination when they fall 
into a clinical risk group who are more likely to experience complications following infection such as those 
with IHD [19].  
5.  The effect of antiviral drugs on cardiovascular events 
Only a small number of studies have investigated cardiovascular complications following antiviral use. A 
meta-analysis of six RCTs on the effect of oseltamivir versus placebo among influenza infected adults 
found that antiviral use was associated with a decrease in adverse cardiac events (RR 0.49, 95% CI 0.25-
0.97) [20]. Conversely, results of one RCT suggested that, compared to placebo, oseltamivir may increase 
QTc prolongations during treatment periods (risk difference 4.0%, 95% CI 0.71-7.30) [20]. Another meta-
analysis of 11 RCTs investigating the effect of zanamivir use in influenza-infected adults found no 
difference (RR 0.98, 95% CI 0.50-1.91) in adverse events affecting the ‘cardiovascular body system’ [20]. 
The association between oseltamivir and cardiovascular complications also been explored in observational 
research. A historical cohort study among adult US military health beneficiaries with CVD identified a 
reduction in the incidence of recurrent cardiovascular events within 30 days among the oseltamivir 
treatment group (OR 0.42, 0.35-0.50) [21]. In another historical cohort study, oseltamivir use resulted in a 
28% (HR 0.72, 95% CI 0.62-0.82) reduction in stroke and transient ischaemic attack risk during the 
subsequent six months [22].  
Antiviral drugs are recommended for influenza prophylaxis and treatment. Prophylactic use may occur if 
antigenic mismatch between seasonal vaccine strains and circulating strains occurs, or as post-exposure 
prophylaxis, particularly to control outbreaks in residential care communities. Antiviral treatment within 48 
hours of symptom onset during influenza seasons in certain clinical risk groups (i.e. IHD) and 
immunosuppressed adults aged ≥65 years is also recommended [19]. 
6. Future research directions 
More research focused on who is at risk of cardiovascular complications triggered by ARIs is needed. 
Predicting future CVD, particularly in people with different combinations of co-morbid conditions, will 
assist in providing targeted personalized interventions. Any expansion to current vaccine recommendations 
resulting from new patient groups being identified as high risk for cardiovascular complications following 
ARI will require effectiveness and cost-effectiveness studies.  
In addition, vaccine uptake among those currently recommended to receive it is suboptimal: across Europe, 
influenza vaccination coverage remains well below the 75% target level among at-risk groups [19]. 
Identifying the optimum vaccine target groups whom vaccination campaigns should be aimed at, as well as 
understanding healthcare barriers and facilitators to uptake should be prioritized. The timing and dose of 
vaccines are also important research considerations. One SCCS study identified a significant reduction in 
the incidence of MI within 60 days of vaccination, particularly in the first two weeks [23]. Some RCTs 
have investigated the impact of high dose influenza vaccine; compared to standard dose vaccine, use of 
high dose vaccine in people with high cardiovascular risk resulted in a greater reduction of cardiovascular 
complications [16]. A large RCT with nearly 10,000 CVD patients is currently underway to determine 
whether high dose influenza vaccine will reduce all-cause mortality and cardiovascular hospitalizations 
[24].  
While prevention of ARIs themselves is likely to result in the greatest clinical and public health benefit, 
treatment during the acute phase of infection could also prevent cardiovascular complications. A better 
understanding of the cardiovascular effects of antivirals is needed e.g. from RCTs with the primary 
outcome of cardiovascular complications. Some observational studies have investigated whether other 
drugs including statins, corticosteroids and antiplatelet agents may potentially reduce risk of CVD events 
during acute infections [25-27]. Further research is needed on the effectiveness, timing and target 
populations for any such treatments. Observational research suggests cardiac biomarkers provide one 
method to identify patients with ARI who are at high risk of cardiovascular complications [28]. This cohort 
study identified hospitalized CAP patients who had blood samples taken at several time points during the 
first 30 days of admission and showed multiple biomarkers were higher among patients who had a 
cardiovascular event. People with high overall vascular risk score, such as Framingham or QRISK, are 
another group who could be targeted for early intervention.    
7. Conclusions 
Understanding and addressing interactions between diseases, such as ARIs and CVD, is increasingly 
important as the global population ages and multimorbidity increases. Among ARIs, much focus has been 
given to influenza due to its severity but also because it is one of the only respiratory infections for which 
there is effective prevention and treatment. This focus is supported by findings from observational studies 
which confirm an association between laboratory-confirmed ARIs and cardiovascular complications. 
However, where infections other than preventable and treatable influenza or S. pneumoniae result in 
cardiovascular complications, other approaches to avert these outcomes are required.    
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